{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '1261 Liberty Way',
 'address2': 'Suite C',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 22.99,
 'askSize': 900,
 'averageDailyVolume10Day': 17700,
 'averageVolume': 35155,
 'averageVolume10days': 17700,
 'beta': None,
 'beta3Year': None,
 'bid': 11.16,
 'bidSize': 1000,
 'bookValue': 4.67,
 'category': None,
 'circulatingSupply': None,
 'city': 'Vista',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.8,
 'dayLow': 11.12,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -8.559,
 'enterpriseToRevenue': 2.504,
 'enterpriseValue': 101943264,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 12.036285,
 'fiftyTwoWeekHigh': 29.858,
 'fiftyTwoWeekLow': 10.29,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 2669614,
 'forwardEps': -1.48,
 'forwardPE': -7.682432,
 'fromCurrency': None,
 'fullTimeEmployees': 153,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.34021,
 'heldPercentInstitutions': 0.57799,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/avisetest.com',
 'longBusinessSummary': 'Exagen Inc. develops and commercializes testing '
                        'products for the diagnosis, prognosis, and monitoring '
                        'of complex autoimmune and autoimmune-related diseases '
                        'under the AVISE brand. It offers AVISE CTD, a '
                        'comprehensive test that aids in the differential '
                        'diagnosis of Systemic Lupus Erythematosus (SLE) '
                        'versus other common connective tissue diseases '
                        '(CTDs); AVISE Lupus testing product that measures '
                        'activation of the complement system by quantifying '
                        "the level of BC4d and EC4d in the patient's blood; "
                        'and AVISE APS, which consists of a panel of eight '
                        'autoantibody tests that aids in the diagnosis and '
                        'management of APS. The company also provides AVISE '
                        'SLE Prognostic, which comprise a ten-biomarker panel '
                        'of autoantibodies that have established predictive '
                        'value for assessing the potential for complications '
                        'affecting the kidney, brain, and cardiovascular '
                        'system; AVISE Anti-CarP test, which identifies '
                        'rheumatoid arthritis (RA) patients with more severe '
                        'disease requiring more aggressive therapy, such as '
                        'anti-TNF biologics; and AVISE PC4d, a cell-bound '
                        'complement activation product biomarker that measures '
                        'platelet- bound C4d, or PC4d. In addition, it offers '
                        'AVISE SLE Monitor, a six-biomarker blood test; AVISE '
                        'MTX, a patented and validated blood test that '
                        'measures levels of MTXPG; and AVISE HCQ, a blood test '
                        'designed to help rheumatologists objectively monitor '
                        'levels of hydroxychloroquine. The company was '
                        'formerly known as Exagen Diagnostics, Inc. and '
                        'changed its name to Exagen Inc. in January 2019. '
                        'Exagen Inc. was incorporated in 2002 and is '
                        'headquartered in Vista, California.',
 'longName': 'Exagen Inc.',
 'market': 'us_market',
 'marketCap': 143719072,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_8444750',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -31024000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.8,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '760-560-1501',
 'previousClose': 11.83,
 'priceHint': 2,
 'priceToBook': 2.4346895,
 'priceToSalesTrailing12Months': 3.530227,
 'profitMargins': -0.36591998,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.8,
 'regularMarketDayLow': 11.12,
 'regularMarketOpen': 12.8,
 'regularMarketPreviousClose': 11.83,
 'regularMarketPrice': 12.8,
 'regularMarketVolume': 39300,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 12640200,
 'sharesPercentSharesOut': 0.0172,
 'sharesShort': 217722,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 113018,
 'shortName': 'Exagen Inc.',
 'shortPercentOfFloat': 0.0417,
 'shortRatio': 5.61,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'XGN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -72.271,
 'twoHundredDayAverage': 15.865288,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'f7ab59e9-d9f4-3c5d-832f-b0d9d20e8d13',
 'volume': 39300,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://avisetest.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92081'}